Inhibitors of the BET bromodomain proteins are promising cancer therapeutics, but tumour cells are likely to become resistant to these drugs. Anticipated mechanisms of resistance have now been described. See Letter p.413
This is a preview of subscription content, log in via an institution to check access.
Notes
References
Klijn, C. et al. Nature Biotechnol. 33, 306–312 (2015).
Lackner, M. R., Wilson, T. R. & Settleman, J. Future Oncol. 8, 999–1014 (2012).
Baylin, S. B. & Jones, P. A. Nature Rev. Cancer 11, 726–734 (2011).
Rathert, P. et al. Nature 525, 543–547 (2015).
Fong, C. Y. et al. Nature 525, 538–542 (2015).
Shu, S. et al. Nature 529, 413–417 (2016).
Eilers, M. & Eisenman, R. N. Genes Dev. 22, 2755–2766 (2008).
Qi, J. Cold Spring Harb. Perspect. Biol. 6, a018663 (2014).
Wang, Y. et al. Science 327, 1650–1653 (2010).
Singh, A. & Settleman, J. Oncogene 29, 4741–4751 (2010).
Author information
Authors and Affiliations
Corresponding author
Related links
Rights and permissions
About this article
Cite this article
Settleman, J. Bet on drug resistance. Nature 529, 289–290 (2016). https://doi.org/10.1038/nature16863
Published:
Issue Date:
DOI: https://doi.org/10.1038/nature16863
- Springer Nature Limited
This article is cited by
-
Targeting bromodomain-containing proteins: research advances of drug discovery
Molecular Biomedicine (2023)
-
A review on reported phytochemicals as druggable leads with antimalarial potential
Medicinal Chemistry Research (2023)
-
Regulation of programmed cell death by Brd4
Cell Death & Disease (2022)
-
Resistance to BET inhibitors in lung adenocarcinoma is mediated by casein kinase phosphorylation of BRD4
Oncogenesis (2021)
-
Ferritinophagy is required for the induction of ferroptosis by the bromodomain protein BRD4 inhibitor (+)-JQ1 in cancer cells
Cell Death & Disease (2019)